ACAD Acadia Pharmaceuticals Inc

Price (delayed)

$16.51

Market cap

$2.67B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$2.58B

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
The EPS has increased by 23% YoY and by 4.5% QoQ
The net income is up by 22% year-on-year and by 4.6% since the previous quarter
The quick ratio has declined by 33% year-on-year
The company's equity fell by 23% YoY and by 2.2% QoQ

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
161.84M
Market cap
$2.67B
Enterprise value
$2.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.13
Price to sales (P/S)
5.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.04
Earnings
Revenue
$512.4M
EBIT
-$203.83M
EBITDA
-$201.28M
Free cash flow
-$129.64M
Per share
EPS
-$1.27
Free cash flow per share
-$0.8
Book value per share
$2.69
Revenue per share
$3.17
TBVPS
$3.79
Balance sheet
Total assets
$612.77M
Total liabilities
$177.92M
Debt
$54.69M
Equity
$434.85M
Working capital
$414.84M
Liquidity
Debt to equity
0.13
Current ratio
4.53
Quick ratio
4.34
Net debt/EBITDA
0.45
Margins
EBITDA margin
-39.3%
Gross margin
97.7%
Net margin
-39.9%
Operating margin
-40.3%
Efficiency
Return on assets
-30.8%
Return on equity
-41.2%
Return on invested capital
-44.1%
Return on capital employed
-41.2%
Return on sales
-39.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
0.67%
1 week
-0.66%
1 month
8.05%
1 year
-6.09%
YTD
-29.26%
QTD
17.18%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$512.4M
Gross profit
$500.65M
Operating income
-$206.63M
Net income
-$204.62M
Gross margin
97.7%
Net margin
-39.9%
The net margin has increased by 29% YoY and by 8% QoQ
The operating margin has increased by 29% YoY and by 8% QoQ
The net income is up by 22% year-on-year and by 4.6% since the previous quarter
The operating income has grown by 22% YoY and by 4.6% from the previous quarter

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.13
P/S
5.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.04
The EPS has increased by 23% YoY and by 4.5% QoQ
ACAD's price to book (P/B) is 31% lower than its 5-year quarterly average of 8.8 and 4.8% lower than its last 4 quarters average of 6.4
The company's equity fell by 23% YoY and by 2.2% QoQ
ACAD's P/S is 67% below its 5-year quarterly average of 15.5 and 19% below its last 4 quarters average of 6.4
ACAD's revenue is up by 11% YoY and by 3.9% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital is up by 37% year-on-year and by 4.1% since the previous quarter
The ROS has increased by 29% YoY and by 8% QoQ
Acadia Pharmaceuticals's return on assets has increased by 10% YoY
The ROE has grown by 4.4% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The current ratio has contracted by 33% YoY
The quick ratio has declined by 33% year-on-year
The debt is 87% lower than the equity
The debt to equity has grown by 30% year-on-year and by 8% since the previous quarter
The company's equity fell by 23% YoY and by 2.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.